Last reviewed · How we verify

Immunotherapeutic GSK2302025A, different formulations

GlaxoSmithKline · Phase 1 active Biologic

Immunotherapeutic GSK2302025A, different formulations is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development. Also known as: PRAME ASCI.

At a glance

Generic nameImmunotherapeutic GSK2302025A, different formulations
Also known asPRAME ASCI
SponsorGlaxoSmithKline
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Immunotherapeutic GSK2302025A, different formulations

What is Immunotherapeutic GSK2302025A, different formulations?

Immunotherapeutic GSK2302025A, different formulations is a Biologic drug developed by GlaxoSmithKline.

Who makes Immunotherapeutic GSK2302025A, different formulations?

Immunotherapeutic GSK2302025A, different formulations is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Immunotherapeutic GSK2302025A, different formulations also known as anything else?

Immunotherapeutic GSK2302025A, different formulations is also known as PRAME ASCI.

What development phase is Immunotherapeutic GSK2302025A, different formulations in?

Immunotherapeutic GSK2302025A, different formulations is in Phase 1.

Related